Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Enzalutamide/ADT Shows Long-Term Survival Benefit in mHSPC Regardless of Prior Local Treatment

May 14th 2022, 8:33pm

American Urological Association Annual Meeting

Enzalutamide added to androgen deprivation therapy demonstrated a benefit in overall survival, radiographic progression-free survival, undetectable prostate-specific antigen rates, objective response rates, and other end points vs placebo/ADT in patients with metastatic hormone-sensitive prostate cancer regardless of whether or not they received prior local therapy.

ARAFOR Data Reveal Favorable Safety, Tolerability With Long-Term Darolutamide Exposure in mCRPC

May 14th 2022, 7:37pm

American Urological Association Annual Meeting

Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.

Dr. Markowski on the Efficacy of Sabizabulin in Prostate Cancer

May 14th 2022, 7:22pm

American Urological Association Annual Meeting

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

May 14th 2022, 6:55pm

American Urological Association Annual Meeting

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Niraparib Plus Abiraterone Acetate/Prednisone Achieves Responses in HRR Gene–Altered mCRPC

May 14th 2022, 6:51pm

American Urological Association Annual Meeting

The addition of niraparib to abiraterone acetate and prednisone achieved for promising response rates in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022, 6:44pm

American Urological Association Annual Meeting

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

18F-rhPSMA-7.3 Increases Upstaging of Disease in Recurrent Prostate Cancer

May 13th 2022, 10:02pm

American Urological Association Annual Meeting

PET/CT scans conducted with 18F-rhPSMA-7.3 frequently resulted in post-scan disease upstaging compared with baseline conventional imaging in patients with prostate cancer recurrence.

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

May 13th 2022, 9:56pm

American Urological Association Annual Meeting

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022, 9:07pm

American Urological Association Annual Meeting

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13th 2022, 9:05pm

American Urological Association Annual Meeting

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

Entrectinib Continues to Yield Promising Data in NTRK Fusion–Positive Breast Cancer

May 11th 2022, 4:00pm

ESMO Breast Cancer Virtual Meeting

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Abemaciclib Plus Endocrine Therapy Elicits Efficacy in High-Risk, HR+ Early Breast Cancer Regardless of Menopausal Status

May 10th 2022, 1:17pm

ESMO Breast Cancer Virtual Meeting

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

May 9th 2022, 7:25pm

ESMO Breast Cancer Virtual Meeting

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity

May 8th 2022, 10:00am

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer

May 7th 2022, 10:00am

Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.

Adjuvant Abemaciclib Plus Endocrine Therapy Has Robust Efficacy in monarchE Cohort of High-Risk, HR+ Breast Cancer

May 6th 2022, 11:20pm

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.

Pembrolizumab Plus Chemotherapy Does Not Significantly Affect QOL in PD-L1+ TNBC

May 6th 2022, 9:30pm

The addition of pembrolizumab to chemotherapy led to significant survival benefits without substantial deterioration in health-related quality of life among patients with treatment-naïve, PD-L1–positive advanced triple-negative breast cancer according to results from the phase 3 KEYNOTE-355 trial.

Evidence Grows to Support Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer and Active Brain Metastases

May 6th 2022, 7:35pm

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

Alpelisib Plus Endocrine Therapy Yields Similar PFS Benefits in Subgroup Analysis of PIK3CA-Mutated, HR+ Breast Cancer

May 6th 2022, 7:09pm

ESMO Breast Cancer Virtual Meeting

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer

May 6th 2022, 4:00pm

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.